{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:12:56Z","timestamp":1776057176602,"version":"3.50.1"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.105035","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:49:15Z","timestamp":1592394555000},"page":"105035","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["ZLY032, the first-in-class dual FFA1\/PPAR\u03b4 agonist, improves glucolipid metabolism and alleviates hepatic fibrosis"],"prefix":"10.1016","volume":"159","author":[{"given":"Zheng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zongtao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liming","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105035_bib0005","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2020.105035_bib0010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(11)60679-X","article-title":"National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants","volume":"378","author":"Danaei","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.105035_bib0015","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2020.105035_bib0020","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/14740338.2013.752813","article-title":"A review of the efficacy and safety of oral antidiabetic drugs","volume":"12","author":"Stein","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2020.105035_bib0025","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14740338.2019.1626823","article-title":"An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors","volume":"18","author":"Lamos","year":"2019","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2020.105035_bib0030","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.105035_bib0035","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.105035_bib0040","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3748\/wjg.v22.i44.9674","article-title":"Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV","volume":"22","author":"Lonardo","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105035_bib0045","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/hep.29724","article-title":"Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.105035_bib0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nature01478","article-title":"Free fatty acids regulate insulin secretion from pancreatic \u03b2 cells through GPR40","volume":"422","author":"Itoh","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2020.105035_bib0055","doi-asserted-by":"crossref","first-page":"11303","DOI":"10.1074\/jbc.M211495200","article-title":"The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids","volume":"278","author":"Briscoe","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0060","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1021\/acs.chemrev.6b00056","article-title":"Complex pharmacology of free fatty acid receptors","volume":"117","author":"Milligan","year":"2017","journal-title":"Chem. Rev."},{"key":"10.1016\/j.phrs.2020.105035_bib0065","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.ajpath.2018.01.009","article-title":"A newly discovered antifibrotic pathway regulated by two fatty acid receptors GPR40 and GPR84","volume":"188","author":"Gagnon","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2020.105035_bib0070","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/13543784.2016.1189530","article-title":"Free fatty acid receptor agonists for the treatment of type 2 diabetes: drugs in preclinical to phase II clinical development","volume":"25","author":"Li","year":"2016","journal-title":"Expert Opin. Investig. Drug"},{"key":"10.1016\/j.phrs.2020.105035_bib0075","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1002\/med.21441","article-title":"Free fatty acid receptor 1 (FFAR1) as an emerging therapeutic target for type 2 diabetes mellitus: recent progress and prevailing challenges","volume":"38","author":"Li","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.phrs.2020.105035_bib0080","first-page":"1","article-title":"Current status of GPR40\/FFAR1 modulators in medicinal chemistry (2016-2019): a patent review","author":"Li","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2020.105035_bib0085","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.bioorg.2018.01.039","article-title":"Structure-based optimization of free fatty acid receptor 1 agonists bearing thiazole scaffold","volume":"77","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0090","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.bioorg.2018.06.039","article-title":"Structure-based design of free fatty acid receptor 1 agonists bearing non-biphenyl scaffold","volume":"80","author":"Li","year":"2018","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0095","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1016\/j.bmc.2018.07.050","article-title":"Nitric oxide donor-based FFA1 agonists: design, synthesis and biological evaluation as potential anti-diabetic and anti-thrombotic agents","volume":"26","author":"Li","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2020.105035_bib0100","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.ejmech.2019.06.087","article-title":"Design, synthesis and biological evaluation of novel FFA1\/GPR40 agonists: new breakthrough in an old scaffold","volume":"179","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103209","article-title":"Discovery of HWL-088: a highly potent FFA1\/GPR40 agonist bearing a phenoxyacetic acid scaffold","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0110","doi-asserted-by":"crossref","DOI":"10.1186\/s13148-015-0149-2","article-title":"Promoter methylation status and expression of PPAR-gamma gene are associated with prognosis of acute-on-chronic hepatitis B liver failure","volume":"7","author":"Zhao","year":"2015","journal-title":"Clin. Epigenet."},{"key":"10.1016\/j.phrs.2020.105035_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2020.105035_bib0120","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","article-title":"PPAR gamma signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2020.105035_bib0125","first-page":"7","article-title":"Clinical interest of PPARs ligands - particular benefit in type 2 diabetes and metabolic syndrome","volume":"30","author":"Verges","year":"2004","journal-title":"Diabetes Metab."},{"key":"10.1016\/j.phrs.2020.105035_bib0130","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1073\/pnas.0510815103","article-title":"Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.105035_bib0135","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.bbadis.2004.11.011","article-title":"Roles of PPAR delta in lipid absorption and metabolism: a new target for the treatment of type 2 diabetes","volume":"1740","author":"Luquet","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2020.105035_bib0140","article-title":"Insights into the role of PPAR beta\/delta in NAFLD","volume":"19","author":"Chen","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105035_bib0145","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1053\/j.gastro.2011.01.045","article-title":"PPAR beta\/delta activation induces enteroendocrine l cell GLP-1 production","volume":"140","author":"Daoudi","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105035_bib0150","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cmet.2013.10.012","article-title":"Desnutrin\/ATGL activates PPAR delta to promote mitochondrial function for insulin secretion in islet beta cells","volume":"18","author":"Tang","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2020.105035_bib0155","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030913","article-title":"PPARbeta\/delta: a key therapeutic target in metabolic disorders","volume":"19","author":"Palomer","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2020.105035_bib0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2018.12.069","article-title":"Discovery of first-in-class thiazole-based dual FFA1\/PPARdelta agonists as potential anti-diabetic agents","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0165","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ejmech.2018.09.071","article-title":"Design, synthesis, and biological evaluation of novel pan agonists of FFA1, PPAR gamma and PPAR delta","volume":"159","author":"Li","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2019.103254","article-title":"Design, synthesis, and biological evaluation of novel dual FFA1 (GPR40)\/PPAR delta agonists as potential anti-diabetic agents","volume":"92","author":"Li","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2015.08.108","article-title":"Animal models for diabetes: understanding the pathogenesis and finding new treatments","volume":"99","author":"Kingand","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105035_bib0180","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2020.105035_bib0185","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1194\/jlr.M800042-JLR200","article-title":"Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet","volume":"49","author":"Rinella","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.phrs.2020.105035_bib0190","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.stem.2015.07.010","article-title":"Circulating IGF-I and IGFBP3 levels control human colonic stem cell function and are disrupted in diabetic enteropathy","volume":"17","author":"D\u2019Addio","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.phrs.2020.105035_bib0195","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.3389\/fimmu.2018.01387","article-title":"Prostaglandin E2 stimulates the expansion of regulatory hematopoietic stem and progenitor cells in type 1 diabetes","volume":"9","author":"Ben Nasr","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2020.105035_bib0200","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.metabol.2017.08.010","article-title":"Pharmacotherapy of type 2 diabetes: an update","volume":"78","author":"Upadhyay","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2020.105035_bib0205","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1126\/science.1204265","article-title":"Human fatty liver disease: old questions and new insights","volume":"332","author":"Cohen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.phrs.2020.105035_bib0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104679","article-title":"A novel FFA1 agonist, CPU025, improves glucose-lipid metabolism and alleviates fatty liver in obese-diabetic (ob\/ob) mice","volume":"153","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.105035_bib0215","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1111\/bph.14980","article-title":"HWL-088, a new potent free fatty acid receptor 1 (FFAR1) agonist, improves glucolipid metabolism and acts additively with metformin in ob\/ob diabetic mice","volume":"177","author":"Chen","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2020.105035_bib0220","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.30429","article-title":"Modulation of insulin resistance in nonalcoholic fatty liver disease","volume":"70","author":"Khan","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.phrs.2020.105035_bib0225","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.phrs.2018.12.008","article-title":"Idebenone and T2D: a new insulin-sensitizing drug for personalized therapy","volume":"139","author":"Dassano","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2020.105035_bib0230","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1073\/pnas.0604628103","article-title":"Phosphoinositide 3-kinase regulatory subunit p85 alpha suppresses insulin action via positive regulation of PTEN","volume":"103","author":"Taniguchi","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.phrs.2020.105035_bib0235","doi-asserted-by":"crossref","first-page":"37489","DOI":"10.1074\/jbc.M506967200","article-title":"Increased p85 alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess","volume":"280","author":"Barbour","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0240","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.2337\/db09-0232","article-title":"FoxO1 links insulin resistance to proinflammatory cytokine IL-1 beta production in macrophages","volume":"58","author":"Su","year":"2009","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2020.105035_bib0245","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1074\/jbc.RA118.006031","article-title":"Forkhead box protein O1 (FoxO1) regulates hepatic serine protease inhibitor B1 (serpinB1) expression in a non-cell-autonomous fashion","volume":"294","author":"El Ouaamari","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0250","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"96","author":"Bays","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2020.105035_bib0255","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/hep4.1072","article-title":"The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice","volume":"1","author":"Haczeyni","year":"2017","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.phrs.2020.105035_bib0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.103803","article-title":"Discovery of novel dual PPARalpha\/delta agonists based on benzimidazole scaffold for the treatment of non-alcoholic fatty liver disease","volume":"99","author":"Li","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.phrs.2020.105035_bib0265","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1161\/CIRCRESAHA.107.165472","article-title":"Role of mitochondrial dysfunction in insulin resistance","volume":"102","author":"Kim","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2020.105035_bib0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mito.2005.10.004","article-title":"Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it","volume":"6","author":"Begriche","year":"2006","journal-title":"Mitochondrion"},{"key":"10.1016\/j.phrs.2020.105035_bib0275","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/17474124.2018.1530110","article-title":"An update on the recent advances in antifibrotic therapy","volume":"12","author":"Tackeand","year":"2018","journal-title":"Expert Rev. Gastroentrol. Hepatol."},{"key":"10.1016\/j.phrs.2020.105035_bib0280","doi-asserted-by":"crossref","first-page":"E1369","DOI":"10.1073\/pnas.1202464109","article-title":"Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist","volume":"109","author":"Iwaisako","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:18:41Z","timestamp":1760912321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820313438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":56,"alternative-id":["S1043661820313438"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105035","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ZLY032, the first-in-class dual FFA1\/PPAR\u03b4 agonist, improves glucolipid metabolism and alleviates hepatic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105035"}}